CD47 and myelodysplastic syndrome: Similarly, trials using other anti‐CD47 monoclonal antibody (evorpacept, NCT04417517 and NCT04755244) have been terminated as the combination “did not substantially improve upon the historical activity of azacitidine alone.” Currently, there is one open trial of anti‐CD47 antibody with HMA in AML and high‐risk MDS (NCT06008405, Table 4), demonstrating continued interest in this target.